ATTIVITA’ FISICA: IL MICROBIOTA RINGRAZIA! MAI DIMENTICARE DI SUGGERIRLA. UNA MAGNIFICA REVISIONE SUI MECCANISMI MOLECOLARI. DA “GASTROENTEROLOGY” (FREE!)

GASTROENTEROLOGIA, MEDICINA DEI PROBIOTICI, MEDICINA INTERNA, NEWSLETTER, Senza categoria

Exercise, Gut Microbiome, and Gastrointestinal Diseases: Therapeutic Impact and Molecular Mechanisms John A. Hawley et al. Abstract The benefits of regular physical activity (PA) on disease prevention and treatment outcomes have been recognized for centuries. However, only recently has interorgan communication triggered by the release of “myokines” from contracting skeletal muscles emerged as a putative mechanism…

INTELLIGENZA ARTIFICIALE: ChatGPT VALUTA LA VALIDITA’ DI UN TRIAL AL PARI DELL’OSSERVATORE UMANO! IMPORTANTE O META-ANALISTI! DA”J OF CLINICAL EPIDEMIOLOGY” (FREE!)

GASTROENTEROLOGIA, METODOLOGIA, NEWSLETTER, Senza categoria

Using artificial intelligence to semi-automate trustworthiness assessment of randomized controlled trials: a case study Ling Shan A et al. Highlights • Problematic RCT data are common, but detection is time-consuming and labor-intensive. • Case study of ChatGPT’s potential to semi-automate trustworthiness assessments. • ChatGPT shows strong capability in extracting and synthesizing information from RCTs. • ChatGPT…

GESTIONE DELL’ULCERA PERFORATA. OCCHIO ALLE NUOVE TECNICHE ED AI NUOVI SCORE DI MORTALITA’, O CHIRURGHI! DA”JAMA SURGERY” (FREE!)

CHIRURGIA, ENDOSCOPIA, GASTROENTEROLOGIA, MEDICINA INTERNA, NEWSLETTER, Senza categoria

Management of Perforated Peptic Ulcer: A Review Seyed A. Arshad et al. Abstract Importance  Perforated peptic ulcer disease (PUD) affects 4 million people annually worldwide, with a lifetime prevalence of 5% to 10%. Of those affected, 5% will progress to the point of perforation. Despite advances in the understanding and treatment, perforated PUD continues to have a…

IBD. OK , MA SI POSSONO SOSPENDERE GLI anti-TNF NEI PAZIENTI IN REMISSIONE CLINICA ED ENDOSCOPICA? LO STUDIO GETECCU. DA”GUT” (FREE!)

GASTROENTEROLOGIA, IBD, NEWSLETTER, Senza categoria

Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU Javier P Gisbert et al on behalf of the EXIT Study group of GETECCU Abstract Background and objectives Primary objectives: to compare the rates of sustained clinical remission at 12 months in patients treated with antitumour necrosis factor…